In this experimental and computational study, 3 biophysical models are developed and evaluated for their ability to accurately describe in vivo growth and response after whole-brain radiation therapy. Models that include reduced proliferation after radiation therapy more accurately predicted future tumor growth.
Introduction
For glioblastoma multiforme patients, radiation therapy is typically administered after surgical resection to target any residual or inoperable cancer (1) . Unfortunately, with the current standard-of-care therapy, nearly all glioblastoma patients have progressive disease 7 to 10 months after adjuvant treatment (2) . Individualizing predictive models on a patient-specific basis (3) could optimize radiation therapy plans for the individual patient, to both maximize tumor cell death and minimize exposure of healthy tissue. Several groups have studied incorporating patient-specific imaging information into biophysical models of tumor growth (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , and recently these models have begun to include response to radiation therapy (15) .
Response to radiation therapy is commonly modeled using the linear-quadratic (LQ) model, and this formalism has been incorporated into several mathematical models of radiation therapy response and planning (16) (17) (18) (19) (20) (21) that use medical imaging data to initialize and constrain patientspecific tumor simulations (3) . One such model, by Rockne et al (16, 17) , uses magnetic resonance imaging (MRI) data acquired before and after the start of treatment to evaluate various dose schedules or estimate a patient's radiosensitivity. Corwin et al (18) expanded upon Rockne et al's model to demonstrate an approach for individualizing intensity modulated radiation therapy plans. The simulated optimized plans had a decreased exposure to normal tissue and increased time to progression, by 63% to 93% and 21% to 105%, respectively, compared with the simulated standard of care. Badoual et al (20) incorporated a model of edema in addition to radiation therapy response to recapitulate observations of posteradiation therapy growth delay. Although these patient-specific radiation therapy models demonstrate the potential value modeling has for clinical radiation therapy, the accuracy and precision of these modeling approaches need to be validated with in vivo experiments. Toward this end, in vivo imaging measurements and histologic sections are used in this study to assess the model prediction error of 3 models of response to radiation therapy.
In this contribution we systematically evaluate the ability of 3 biophysical models to describe and predict the in vivo spatio-temporal development of C6 glioma growth after radiation therapy differentiated by (1) cell death immediately after radiation therapy (or M d model); (2) a reduction of proliferation rate after radiation therapy (or M p model); and (3) the combination of cell death and reduced proliferation rate (or M dp model). Diffusion-weighted MRI (DW-MRI) and contrast-enhanced MRI (CE-MRI) data acquired before and after radiation therapy are used to estimate tumor cell count. The M d model is related to the LQ model resulting in immediate cell death; that is, after irradiation some fraction of the cells lose their clonogenic survival, eventually resulting in predominantly apoptosis or necrosis. The M d model assumes that the effect of radiation therapy (ie, cell death) occurs over a relatively short period. The M p model assumes that irradiation predominantly result in a reduced net proliferation of tumor cells. A dosedependent reduction in proliferation rate has been observed in the C6 line (22) and may be due to cell cycle arrest (23) or senescence. The M p model, however, assumes that the effect of radiation therapy is a long-term alteration of growth kinetics. The M dp model incorporates the effects of both reduced proliferation and cell death to model posteradiation therapy growth, providing a balance between the short-and long-term effects of radiation therapy. The M d , M p , and M dp models are then fit to the measured 3-dimensional tumor cell count time courses. The estimated model parameters are then used to predict future tumor growth and response. The discrepancy between the model prediction and the measured data is assessed at the posteradiation therapy time points. The model prediction is also compared with postmortem histologic analysis.
Methods and Materials

In vivo experiments
The experimental procedures were approved by our Institutional Animal Care and Use Committee. Rats were anesthetized with 2% isoflurane in 98% oxygen for all imaging, surgical, and irradiation procedures. Twelve female Wistar rats (257 AE 9 g, mean AE 95% confidence interval) were anesthetized and inoculated intracranially with 10 5 C6 glioma cells via stereotaxic injection on day 0. On day 8, permanent jugular catheters were placed in each rat for injection of an MRI contrast agent. Rats were imaged 3 times before treatment (days 10, 12, and 14, or t 1 through t 3 ) and 4 times after treatment (days 16.5, 18.5, 20.5, and 22.5, or t 4 through t 7 ). Magnetic resonance images were acquired using a 9.4T horizontal-bore magnet (Agilent, Santa Clara, CA). A pulsed Volume 100 Number 5 2018 Biophysical models of RT response 1271 gradient fast spin echo DW-MRI (24, 25) sequence was used to measure the apparent diffusion coefficient (ADC), which was then used to estimate tissue cellularity as previously described (8, 9, (26) (27) (28) . A T 1 map acquired using an inversion-recovery snapshot experiment was used to identify anatomic regions. A spoiled gradient echo CE-MRI experiment was used to identify tumor regions of interests after the injection of a 200-mL bolus (0.05 mmol kg À1 ) of gadoliniumdiethylenetriamine-pentaacetic acid (Gado-DTPA; BioPal, Worcester, MA). Magnetic resonance images were acquired over a 32 Â 32 Â 16-mm 3 field of view sampled with a 128 Â 128 Â 16 matrix (250 Â 250 Â 1000-mm voxel resolution). Additional MRI experimental details are reported in the Supplementary Material (available online at www.redjournal.org).
Rats were irradiated with 20 Gy (n Z 5) or 40 Gy (n Z 7) at a dose rate of 2.3 Gy/min with a Therapax DXT 300 x-ray machine (300 kVp/10 mA; Pantak, East Haven, CT) on day 14.5 (t rt ). Large single-fraction doses were selected for this initial study to elicit distinct responses for model development and validation. During the irradiation protocol, rats were shielded to minimize exposure outside of the brain. At the conclusion of the last imaging study, animals were killed, and the brain tissue was prepared for histologic sectioning and staining with hematoxylin and eosin and Ki-67. Additional histology details are reported in the Supplementary Material (available online at www.redjournal.org).
Biophysical models of tumor growth
Tumor growth is modeled using Equation 1, which describes the change in the distribution and number of tumor cells due to the random movement of tumor cells (first term on the right-hand side), the proliferation of cells (second term on the right-hand side), and the death of cells due to radiation therapy (third term on right-hand side): ratio and uniform dose distribution). The end result would still be a fraction of cells that do not survive radiation therapy. We decided to then simplify the model to capture this effect as a single parameter that implicitly takes into account dose and radiosensitivity. These 3 models represent natural extensions of the LQ model to incorporate the instantaneous and delayed effects of radiation therapy and do so using imaging data that are available in the clinical setting. Measured values of Nðx; tÞ, N meas ðx; tÞ, are obtained using DW-MRI before and after radiation therapy (27, 28, 30) . Pretreatment (t 1 through t 3 ) measurements of Nðx; tÞ are used to solve an inverse problem (28, 30) to return estimates of qðxÞ, k p ðxÞ, and tumor cell diffusion. Similarly, posttreatment measurements (t 4 through t 5 ) are then used to solve an inverse problem to estimate k d,rt and f p,rt voxel-wise within the tumor. Model parameters were calibrated using a Levenberg-Marquardt least squares algorithm (31, 32) , which minimizes the error between the modeled and measured cellularity. For the M d model, k d,rt is estimated, and f p,rt is set to 1. For the M p model, f p,rt is estimated, and k d,rt is assigned to 0. For the M dp model, both k d,rt and f p,rt are estimated. Literature values used for mechanical tissue properties (discussed in the Supplementary Material; available online at www. redjournal.org) were assigned from excised rat brain samples (33, 34) , though it would be preferable to measure these parameters on an individual basis (potentially through MR elastography [35] ). Literature values were also used to assign cell packing density (36) and the average cell size (37) . We further assume that the packing density and cell size remain constant throughout the duration of the experiment. (Future efforts could use advanced diffusion approaches to measure, for example, changes in cell size [38, 39] ). The estimated model parameters are then used in a forward evaluation of the model system, N model ðx; tÞ, to predict tumor growth at t 6 and t 7 . The finite difference method was used to solve 
Error analysis
The model prediction error was assessed using 2 metrics on days t 6 and t 7 . First, the differences between the predicted and measured tumor size and shape were assessed by calculating the percent error in tumor volume and the average surface distance (ASD), respectively. Second, within overlapping regions of the predicted and measured tumors, the percent error in cell number was calculated. The percent error in tumor volume was determined by calculating the percent difference between the predicted and the measured estimates of tumor volume. The ASD reports the average minimum distance between a voxel on the surface of the model tumor volume and a voxel on the surface of the measured tumor volume. The error in model fit poste radiation therapy was calculated using a weighted sum squared error (wSSE), described in the Supplementary 
N dp (x,t) 
to the total number of cells at each time point. At the voxel level, the percent difference in cell number was calculated between the model and measurement wherever N meas ðx; tÞ was greater than 0. All results are reported as the mean and 95% confidence interval when appropriate. A 1-way analysis of variance was used to evaluate the differences in global and local errors between the model fits within treatment groups. Tukey's honest significant difference test was then used for pair-wise comparisons. A P value of <.05 was considered significant. Pearson's correlation coefficient (r) was calculated between the histology measurements and model parameters.
Results Figures 1 and 2 show measured and modeled number of tumor cells, as well as the percent difference between the 2, from the central tumor slice for representative rats from the 20-Gy and the 40-Gy groups, respectively. For the rat irradiated with 20 Gy, the predictions of the M d model (row d) overestimate tumor size (error greater than 55.7%) on t 6 and t 7 compared with the M p and M dp models (error less than 17.0% and 9.6%, respectively). No significant differences were observed between the models at the voxel level (mean error ranged from 10.2% to 13.2%). Importantly, the M d and M p models fail to capture the developing low cell density region on days t 6 through t 7 (row c, resulting in greater than 50% error in these regions [rows e, g, i]), whereas the M dp model exhibits lower error (less than 30%) in these regions.
For the rat irradiated with 40 Gy, the predictions of the M d model had high error in tumor volume (greater than 114.9%), whereas the M p and M dp had lower error in tumor volume (less than 23.5% and 10.5%, respectively). At the voxel level, no significant difference was observed among the 3 models (average error less than 5.1%). N meas (x,t 7 )
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was observed in the tissue sections. High cell density is observed in both insets A and B, although there are a few low cell density regions (inset A) that appear throughout the tumor. Fewer positive Ki-67 stained cells (64.53% AE 2.90%) were observed compared with the rat irradiated with 20 Gy. The necrosis observed in the rat irradiated with 20 Gy, but not the one irradiated with 40 Gy, is likely due to interanimal variability in tumor growth and response. Figure 5 summarizes the error analysis for both groups of irradiated with 20 (panels a-c, g) and 40 Gy (panels d-f, h). A statistically significant (P < .03) reduction in error was observed at all time points for the M p (error in tumor volume, ASD, error in voxel cell number) and M dp (error in tumor volume, ASD) models compared with the M d model. Similarly, for the rats irradiated with 40 Gy, a statistically significant (P < .04) reduction in error was observed at all time points for the M p and M dp (error in tumor volume, ASD, error in voxel cell number) models compared with the M d model. For both treatment groups, significantly increased wSSE (P < .05) was observed for the M p and M d models compared with the M dp . Additionally, the M p model for the rats irradiated with 20 Gy had significantly decreased wSSE (P < .01) compared with the M d model. Table 1 reports the mean estimated model parameters and their correlation to the percent positive stained Ki-67 cells within tumor regions for both treatment groups. Significant differences were observed between doses for M p and M dp model parameters. Significant (P < .05) and strong correlation was observed for f p,rt for the rats irradiated with 40 Gy (r Z 0.99) and k d,rt for the rats irradiated with 20 Gy (r Z À0.98) parameters estimated for the M dp model and Ki-67 staining. 
M dp M dp
Percent Error in Tumor Volume
Percent Error in Voxel Cell Number The weighted sum squared error (wSSE) is also reported in panels g and h for the 20-Gy and 40-Gy rats, respectively. Generally, high global-level errors were observed for the M d model for both treatment groups, whereas the M dp model resulted in low global-level errors. All models resulted in low local-level errors for the 20-Gy group (panel c), whereas the M d and M dp models had lower error for the 40-Gy group (panel f).
Discussion
The M d model is a variation of the LQ model that has been previously applied (16, (40) (41) (42) to clinical data sets after fractionated radiation therapy. The M d model reflects some of the short-term effects of radiation therapy, including cell death and shrinking of the tumor. Rather than assigning the death rate as the fraction of cells that die because of radiation therapy (16, 17) , we fit the models to time course data to estimate a spatially varying death rate. The negative (although not statistically significant) correlation between k d,rt and percent positive stained Ki-67 cells suggests k d,rt may reflect observed tumor biology. The varied response between the 20-Gy and 40-Gy groups suggests that the M d model may be more valid at low doses, where posteradiation therapy growth kinetics more closely match the untreated growth kinetics ( Fig. E1 ; available online at www.redjournal.org). The M p model is another variation of the LQ model, in which the loss of proliferative ability is modeled as a decrease in the net proliferation rate compared with the pretreatment proliferation rate. Generally, the M p model provided better model predictions compared with the M d model. On the basis of the reduced doubling time observed after radiation therapy ( Fig. E1 ; available online at www.redjournal.org), it was hypothesized that this model may be able to better describe the posteradiation therapy growth kinetics. The positive (although not statistically significant) correlation between f p,rt and percent positive stained Ki-67 cells, as well as the dose dependency of the mean f p,rt , suggests f dp,rt may reflect the observed decrease in tumor proliferation. However, the M p model results in high error in cases in which the tumor volume shrinks or indicates no growth after radiation therapy. The M p model may more accurately describe growth at lower doses; however, it fails to capture decreases in tumor volume after therapy or areas of necrosis. The M dp model combines both short-term and long-term effects (22, 43) . Both the M p and M dp resulted in decreased error (ie, in tumor volume, ASD, and voxel cell number) in model predictions, but the M dp model may provide a better overall description owing to the decrease in wSSE compared with the M p model. The statistically significant differences between the M dp and M p models for the wSSE metric, but not the other metrics, are likely to due to reduced error in both the calibration and prediction phases for the M dp model, which only the wSSE metric assesses. The M dp model may also provide improved predictions of intra-tumor heterogeneity (Figs. 1 and 3) . Model parameters (f p,rt and k d,rt ) seemed to be dose specific, suggesting that a more explicit relationship between dose and f p,rt and k d,rt may exist; this is the subject of ongoing efforts. Comparison of model parameters with histologic staining indicated an inverse relationship between k d,rt and the percent positive stained Ki-67 cells and a positive relationship between f p,rt and Ki-67 staining. The histologic correlation for both parameters suggests that they may provide insight into the underlying tumor biology after radiation therapy (ie, delayed or altered proliferation, reduced number of proliferating cells). The M dp model is a natural extension of previous modeling efforts (16, 17) of response to radiation therapy. The main benefit of the M dp model is the incorporation of both single time-point cell kill and a long-term effect, which more accurately recapitulates in vivo observations of the persistent effect of radiation therapy.
There are several limitations to the present study. One limitation is in the interpretation of imaging measurements after radiation. In this work we use ADC measurements to estimate cell number. Several preclinical and clinical studies have demonstrated a strong correlation between histologic estimates of cellularity in human brain tumors (44) , breast cancer (45), extracranial lesions (46) , small animal models of breast cancer (47) , and in vitro studies (26) . There are, however, other factors (cell membrane permeability [48] , cell size, tortuosity [49] , edema [50] , necrosis [50] ) that can also affect the measured ADC before and after treatment. This approach to transform ADC to cell number must, therefore, be regarded as a first-order approximation to the true tumor cellularity. Contrastenhanced MRI enhancement may also potentially indicate false volume increases or decreases after radiation therapy (51) . Pseudoprogression is often a result of increased inflammation, edema, and vessel permeability and can be challenging to distinguish from actual progression, and separating these 2 phenomena is an active area of research (52) (53) (54) (55) . A second limitation is that there is a lack of histology for untreated rats to which the treated groups can be compared, as well as a lack of histology at the time of treatment. However, the dose-dependent decreases in Ki-67 have been observed by others (43) .
A third limitation is the use of single large doses over the whole brain. Radiation therapy is more commonly delivered in small doses over several fractions with a more focal dose. Large single-fraction doses were selected for this initial study to provide 2 distinct treatment responses from which to test and validate the mathematical models. Ongoing studies will investigate smaller, fractionated dose response.
A fourth limitation is the lack of a validation of the pretreatment parameters. An additional imaging time point could be used to verify the pretreatment parameters; however, that will limit the number of posttreatment time points we could acquire. When applied to a cohort of untreated rats, this modeling approach resulted in less than 2.20% error in tumor volume, average surface distance less than 0.38 mm, and average percent error in voxel cell number less than 13.25% (30) . On the basis of those results we have confidence in the ability of this framework to capture untreated tumor growth. Finally, in a data-limited setting (eg, standard-of-care clinical studies) this approach may not be tenable. However, with the advent of MRI-guided external beam radiation treatment (56) , functional or anatomic data could be acquired on a per-fraction basis. This scenario would produce measurements that can be used to calibrate model parameters (and correct parameters as more data become available) that can be used to adapt the remaining treatment plans (57) .
Conclusion
The models developed and analyzed within this study are an encouraging step toward the development of mathematically rigorous, individualized radiation therapy plans. After receiving 20 Gy, growth can be accurately described using the M p or M dp model. At higher doses the M p and M dp models both resulted in lower error in tumor volume, ASD, and voxel cell number, whereas the M d model poorly described tumor response at high doses. Overall, the M dp model provides a more complete characterization of the posteradiation therapy growth kinetics, although further model development is needed to more accurately characterize the heterogeneous response to radiation therapy within the tumor.
